Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Osteoporosis | Treatment Algorithms | Claims Data Analysis | US | 2019

Login to access report north_east
Contact sales account_box

A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents—Amgen’s Prolia, Eli Lilly’s Forteo, and Radius Health’s Tymlos—are reserved for later lines of therapy, primarily because of their higher prices. This report presents insight into the treatment of a disease in which brands compete for market share in the second and later lines of therapy and combination use is minimal.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients?
  • What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
  • How have Prolia, Forteo, and Tymlos been integrated into the treatment algorithm?
  • What proportion of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of osteoporosis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with osteoporosis?
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
north_east
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
north_east
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east